You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 18, 2025

CLINICAL TRIALS PROFILE FOR SELENOMETHIONINE SE 75


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Selenomethionine Se 75

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00112892 ↗ Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors Completed Roswell Park Cancer Institute Phase 1 2004-08-01 RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Selenium may allow higher doses of irinotecan to be given. Giving irinotecan together with selenium may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of selenium when given together with irinotecan in treating patients with advanced solid tumors.
NCT00212186 ↗ Selenium Supplementation of Patients With Cirrhosis Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) N/A 1998-10-01 The purpose of this study is to determine whether patients with liver disease can improve their nutritional selenium status by taking supplemental selenium.
NCT00212186 ↗ Selenium Supplementation of Patients With Cirrhosis Completed Vanderbilt University N/A 1998-10-01 The purpose of this study is to determine whether patients with liver disease can improve their nutritional selenium status by taking supplemental selenium.
NCT00212186 ↗ Selenium Supplementation of Patients With Cirrhosis Completed Vanderbilt University Medical Center N/A 1998-10-01 The purpose of this study is to determine whether patients with liver disease can improve their nutritional selenium status by taking supplemental selenium.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Selenomethionine Se 75

Condition Name

Condition Name for Selenomethionine Se 75
Intervention Trials
Prostate Cancer 2
Lung Cancer 1
Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity 1
Mucositis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Selenomethionine Se 75
Intervention Trials
Prostatic Neoplasms 3
Carcinoma 2
Laryngeal Neoplasms 1
Squamous Cell Carcinoma of Head and Neck 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Selenomethionine Se 75

Trials by Country

Trials by Country for Selenomethionine Se 75
Location Trials
United States 11
New Zealand 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Selenomethionine Se 75
Location Trials
New York 7
Tennessee 2
Iowa 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Selenomethionine Se 75

Clinical Trial Phase

Clinical Trial Phase for Selenomethionine Se 75
Clinical Trial Phase Trials
Phase 2 4
Phase 1/Phase 2 1
Phase 1 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Selenomethionine Se 75
Clinical Trial Phase Trials
Completed 5
Terminated 3
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Selenomethionine Se 75

Sponsor Name

Sponsor Name for Selenomethionine Se 75
Sponsor Trials
Roswell Park Cancer Institute 6
National Cancer Institute (NCI) 4
Vanderbilt University Medical Center 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Selenomethionine Se 75
Sponsor Trials
Other 14
NIH 5
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Selenomethionine Se-75: Clinical Trials, Market Analysis, and Projections

Introduction

Selenomethionine Se-75, a compound that combines selenium with the amino acid methionine, has been the subject of various clinical trials and market analyses. This article will delve into the current state of clinical trials, market trends, and future projections for Selenomethionine Se-75.

Clinical Trials and Efficacy

Overview of Clinical Trials

Selenomethionine Se-75 has been investigated in several clinical trials, although its current R&D status is listed as withdrawn. Historically, it was developed by Bracco Diagnostics, Inc., and was initially approved in the US in 1973 for use in positron-emission tomography (PET) imaging[4].

Antioxidant and Therapeutic Effects

Studies have shown that selenomethionine can enhance antioxidant capacities. For instance, it induces the cystine/glutamate transporter xc- and increases glutathione levels, which are crucial for cellular protection against oxidative stress[3].

Specific Clinical Findings

  • In a study on cardiac hypertrophy, co-administration of selenomethionine with harmine significantly reduced hypertrophy-related markers, suggesting a potential therapeutic combination for treating cardiac hypertrophy[4].
  • Another study on sea cucumbers found that selenomethionine supplementation improved growth performance and antioxidant enzyme activities, highlighting its beneficial effects in certain biological systems[4].

Limitations and Withdrawal

Despite these findings, the R&D status of Selenomethionine Se-75 is currently withdrawn, indicating that active clinical development has ceased. This could be due to various factors, including lack of significant therapeutic benefits in human trials or safety concerns.

Market Analysis

Global Market Size and Growth

The global market for Selenium-75, which includes Selenomethionine Se-75, is projected to grow from USD 21.13 million in 2023 to USD 32.88 million by 2030, at a Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period[2].

Market Drivers

Several factors drive the demand for Selenium-75:

  • Increasing Medical Demand: Rising cancer incidence rates and advancements in medical imaging technology increase the need for diagnostic tools like Selenium-75, particularly in radioisotope tracing for tumors[2].
  • Expansion of Industrial Applications: The growth in industrial manufacturing, especially in sectors like oil, gas, and construction, increases the demand for non-destructive testing, where Selenium-75 is used[2].
  • Technological Advancements and Research: Progress in radioisotope research and its applications in agricultural and environmental science also boost the market[2].

Market Restraints

Despite the growth, there are significant restraints:

  • High Costs: The expensive production and handling costs due to the radioactive nature of Selenium-75 are major hurdles[2].
  • Specialized Equipment: The need for costly equipment and infrastructure further complicates market expansion[2].

Market Projections

Forecasted Growth

The Selenium-75 market is expected to see steady growth driven by increasing medical and industrial demands. The CAGR of 6.2% from 2023 to 2030 indicates a robust market trajectory, despite the current withdrawal of Selenomethionine Se-75 from active clinical development[2].

Emerging Markets

Industrialization and improvements in medical infrastructure in emerging markets are expected to drive demand for Selenium-75. Enhanced global supply chains and advances in logistics technology will also make the market supply more stable and efficient[2].

Technological Innovations

Advancements in imaging technologies, the development of portable and user-friendly diagnostic devices, and ongoing research into new applications for Selenium-75 will continue to support market growth[2].

Key Players and Market Share

The global top 3 players in the Selenium-75 market account for 80% of the market share in terms of revenue. Key players include Rosatom, China National Nuclear Corporation, and Eckert & Ziegler Strahlen[2].

Regulatory and Safety Aspects

Strict management and safety measures for radioisotopes, along with the formulation and implementation of medical and industrial standards by governments and international organizations, ensure the safe use of Selenium-75. This regulatory support is crucial for market confidence and growth[2].

Conclusion

Selenomethionine Se-75, while currently withdrawn from active clinical development, remains a significant component of the broader Selenium-75 market. The market is driven by increasing medical and industrial demands, technological advancements, and regulatory support. Despite high production and handling costs, the market is projected to grow steadily, with emerging markets and improved supply chains playing key roles.

Key Takeaways

  • Clinical Trials: Selenomethionine Se-75 has shown promise in antioxidant and therapeutic effects but is currently withdrawn from active clinical development.
  • Market Growth: The global Selenium-75 market is projected to grow at a CAGR of 6.2% from 2023 to 2030.
  • Market Drivers: Increasing medical demand, expansion of industrial applications, and technological advancements drive the market.
  • Market Restraints: High costs and the need for specialized equipment are significant restraints.
  • Regulatory Support: Strict safety measures and regulatory standards support market growth.

FAQs

What is the current R&D status of Selenomethionine Se-75?

The R&D status of Selenomethionine Se-75 is currently withdrawn, indicating that active clinical development has ceased[4].

What are the primary uses of Selenium-75?

Selenium-75 is used in medical imaging, particularly in radioisotope tracing for tumors, and in industrial applications such as non-destructive testing[2].

What drives the demand for Selenium-75?

Increasing medical demand, expansion of industrial applications, technological advancements, and regulatory support drive the demand for Selenium-75[2].

What are the major restraints to the Selenium-75 market?

High production and handling costs due to its radioactive nature and the need for specialized equipment are major restraints[2].

Who are the key players in the Selenium-75 market?

Key players include Rosatom, China National Nuclear Corporation, and Eckert & Ziegler Strahlen[2].

Sources

  1. The Clinical Outcomes of Selenium Supplementation - MD Journal
  2. Selenium-75 Industry Analysis - QYResearch
  3. Selenomethionine (Se-Met) Induces the Cystine/Glutamate Transporter - MDPI
  4. Selenomethionine Se-75 - Synapse
  5. Growth of Selenium-75 Market - OpenPR

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.